Search PubMed⌕ Search

Biomedical subjects

M Barbanti

Publications and source records attributed to M Barbanti.

At least 55 records · Page 3Linked to original sources
PubMed1989

Hyperglycemia-conditioned increase in alpha-2-macroglobulin in healthy normal subjects: a phenomenon correlated with deficient antithrombin III activity.

Induced hyperglycemia in normal subjects increases alpha 2-macroglobulin (alpha 2M) activity and alpha 2M concentration and reduces antithrombin III (ATIII) activity, while it does not affect ATIII plasma concentration. Hyperglycemia-determined variations in ATIII activity and alpha 2M molecules are correlated in an inverse and parallel fashion. A compensatory role for the increase in alpha 2M in the regulation of the coagulation system may be hypothesized. Moreover, these data provide evidence that hyperglycemia may decrease, directly, the biological function of some proteins and may influence the levels of some risk factors for the development of complications in diabetes.

Adult↗
PubMed1987

Pharmacokinetics and organ distribution in rats of a low molecular weight heparin.

Fluorescein-labelled low molecular weight heparin (OP/LMWH) pharmacokinetics and organ distribution were studied in the rat after intravenous administration at doses of 3 and 15 mg/kg. The pharmacokinetics of labelled OP/LMWH was dose-dependent like heparin, however, the anticoagulant activity such as anti-Xa was more prolonged. The rapidity of the disappearance of the fluorescence was quicker than the biological activity. The fluorescence was observed mainly in the liver and kidney as a diffuse aspect in the short time and as a globular aspect in the long time, mainly in Disse's space of the liver. These results confirm that the liver is important in the regulation of heparin metabolism and activity.

Animals↗
PubMed1986

Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.

In vitro platelet proaggregating effect of unfractionated heparin (H) and OP/LMWH were studied with human platelets. OP/LMWH produced a significant less potentiation of ADP and PAF induced aggregation and slightly counteracted the antiaggregating effect of PGI2, in comparison with H. The proaggregating effect of both heparins was neutralized by equal contemporaneous amount of protamine sulfate.

Adenosine Diphosphate↗
PubMed1986

Antithrombotic effect of OP/LMWH by subcutaneous route in rats.

The aim of this study was to compare the antithrombotic and haemorrhagic effects of unfractionated heparin and OP/LMWH, a new low molecular weight heparin fragment, after subcutaneous administration in rats. Both heparins showed antithrombotic efficacy in a model of acute venous thrombosis even at 1 mg/kg; furthermore OP/LMWH presented a significantly higher activity in subacute venous thrombosis of the rat. At all the dosages tested OP/LMWH showed a significantly shorter bleeding time in the rat by the "transection" method, compared with unfractionated heparin. This study suggests the possibility of dissociating the antithrombotic and haemorrhagic effects of some heparin fractions.

Animals↗
PubMed1985

Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats.

A new low molecular weight heparin (LMWH) and a conventional unfractionated heparin (H) were tested in rats for venous antithrombotic activity and bleeding tendency after intravenous administration. Both drugs showed antithrombotic activity, but LMWH at the low dosages tested (0.1 and 0.25 mg/kg) demonstrated significantly higher activity than H. In a rat bleeding time test (transection model) both heparins produced a prolonged bleeding time, but LMWH possessed significantly less potency than H at all the dosages tested. Ex vivo coagulation parameters (activated partial thromboplastin time and antiXa activity) were also evaluated: LMWH presented very low activity on the APTT test and a sustained antiXa activity, comparable to that of H.

Animals↗
PubMed1985

Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats.

Fluorescein-labelled sulodexide pharmacokinetics and urinary excretion were studied in the rat after intravenous administration. The compound showed a pharmacokinetic pattern similar to that of heparin and the plasmatic levels were linearly correlated with anti-factor Xa activity and logarithmically with lipoprotein lipase activation. The compound is well eliminated by urinary route; the urinary recovery was 50% in 24 h and 67% 48 h after administration. The results obtained indicate that fluorescein labelling of glycosaminoglycans may be a valid tool for pharmacokinetics and distribution studies in the laboratory animals.

Animals↗
PubMed1984

Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats.

Glycosaminoglycans extracted from various sources are extensively utilized in the treatment of occlusive vascular disease. These products have shown to possess antithrombotic activity in some experimental thrombosis (1,2). Our purpose was to study the activity of Sulodexide, an heparin-like compound (3,4), on rat model of arterial thrombosis and to study its interaction with platelets.

3,4-Methylenedioxyamphetamine↗
PubMed1984

Effect of SAS 650 (Furofenac) on malondialydehyde production by platelets.

The activity of SAS 650, a new anti-inflammatory drug, on ex vivo and in vitro MDA production by platelets was compared to that of aspirin. The drug induced dose-dependent inhibition of in vitro MDA production by rat and guinea-pig platelets and also had good activity after 30 second of incubation in rat platelets, quicker than aspirin. SAS 650 preincubation reduced the in vitro inhibitory effect of ASA, as shown also by ex vivo experiments. The results of the present study support the involvement of SAS 650 in the platelet cyclooxygenase pathway.

Acetates↗
PubMed1984

The effects of hypolipidemic agents derived from procetofenic acid on the activity of superoxide dismutase and glutathione peroxidase and on malonyl dialdehyde production of rat liver.

Male and female rats were treated with hypolipidemic agents derived from procetofenic acid, namely fenofibrate ( procetofene ), cholestyrammonium alpha-(4-p-chlorobenzoyl-phenoxy)-isobutyrate (Alfa-1081) and alpha-(4-p-chlorobenzoyl-phenoxy)-isobutyryl-taurine (35/ipo). A marked decrease of liver superoxide dismutase and glutathione peroxidase was observed in the male rats treated with fenofibrate. In this sample a significant increase of malonyl dialdehyde was also detected when the liver homogenates were subjected to a test of lipid peroxidation induced by active oxygen species. Alfa-1081 and 35/ipo produced no substantial changes of superoxide dismutase and glutathione peroxidase and no significant increase of peroxidation products. These results, while providing an in vivo evidence for the role of superoxide dismutase and glutathione peroxidase as antioxidant enzymes, indicate that hypolipidemic agents can affect also enzymes not bound to membranes as they do with peroxisomal enzymes. The side effect presented here may be harmful, since it can lead to an augmented risk of lipid peroxidation in tissues. It is, however, clear that also within the same class of hypolipidemic drugs the effect is not always present. Peroxidative damage should therefore be considered as a key parameter in the characterization of hypolipidemic agents.

Animals↗
PubMed1980

[Effects of clofibrate on rabbit kidneys].

The Authors have investigated the effect on the kidney of experimental administration of 250 mg of clofibrate in rabbits. After 36 days of treatment the animals are sacrificed and histological and ultrastructural examination are made. The seriographies an alteration of the glomerular membrane and a mild fragmentation of endothelial lamina. Swelling of the proximal tubular cell is also revealed. It is concluded that this early injury of the nephron is reversible and more severe manifestation in man can occur. This drug must be strongly avoided.

Animals↗
PubMed1979

Bone marrow transplantation for severe aplastic anemia. A report of 9 cases.

9 patients with severe aplastic anemia (SAA) were treated with bone marrow transplantation (BMT). 5 were conditioned with cyclophosphamide and received and HLA-identical graft (4 patients) or a mismatched graft (1 patient): 1 rejected the graft on day 30 and died on day 34 during conditioning for a second transplant; 1 died on day 15 with acute and severe graft versus host disease (GvHD) in the absence of haemopoietic engraftment; 3 are alive and complete chimeras at 1,069, 490 and 332 days after transplantation. GvHD developed in 4 patients and was treated successfully in 3 with high dose methylprednisolone and/or antilymphocytic globulin (ALG). 4 patients were conditioned with ALG and received bone marrow from a haploidentical sibling or parent: 1 patient was refractory; 3 patients showed evidence of hematologic reconstitution, but 2 of these required a second course of ALG. 3 patients in this group are alive between 60 and 490 days; 1 patient died on day 121 of HBSAg-negative acute hepatitis.

Adolescent↗